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Synopsis
CAFs (cancer-associated fibroblasts), the most abundant cell type in breast cancer stroma, produce a plethora
of chemokines, growth factors and ECM (extracellular matrix) proteins, that may contribute to dissemination and
metastasis. Axillary nodes are the first metastatic site in breast cancer; however, to the present date, there is
no consensus of which specific proteins, synthesized by CAFs, might be related with lymph node involvement. The
purpose of this study was to perform a systematic review of CAF biomarkers associated with the presence of regional
metastasis. PubMed was searched using the words: ‘breast cancer’ and ‘lymph node’ and fibroblast or stroma or
microenvironment. After exclusions, eight studies evaluating biomarkers immunoexpression in CAFs and lymph node
status were selected. Biomarkers evaluated in these studies may be divided in two groups, according to their ontology:
extracellular matrix components [MMP13 (matrix metalloproteinase 13), TIMP2 (tissue inhibitor of metalloproteinases-
2), THBS1 (thrombospondin 1), LGALS1 (lectin, galactoside-binding, soluble, 1)] and response to wounding [PDPN
(podoplanin), PLAU (plasminogen activator, urokinase), PLAUR (plasminogen activator, urokinase receptor), CAV1
(caveolin 1), THBS1, LGALS1]. A positive expression of MMP13 and LGALS1 in CAFs was associated with enhanced
OR (odds ratio) for regional metastasis. Contrariwise, CAV1 positive staining of fibroblasts was associated with
decreased OR for nodal involvement. Expression of MMP13, PDPN and CAV1 was further tested in a new series of
65 samples of invasive ductal breast carcinomas by immunohistochemistry and no association between biomarkers
expression in CAFs and nodal status was found. It was suggested that breast cancer subtypes may differentially
affect CAFs behaviour. It would be interesting to evaluate the prognostic significance of these biomarkers in CAFs
from different tumour types.
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INTRODUCTION
There is increasing evidence that breast cancer behaviour reflects
an interconnection between the malignant epithelial compartment
and the surrounding microenvironment.
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Abbreviations used: CAFs, cancer-associated fibroblasts; CAV1, caveolin-1; ECM, extracellular matrix; HG3, histological grade 3; LGALS1, lectin, galactoside-binding, soluble, 1;
MMP13, matrix metalloproteinase 13; OR, odds ratio; PDPN, podoplanin; PLAU, plasminogen activator, urokinase; PLAUR, plasminogen activator, urokinase receptor; SI, staining index;
THBS1, thrombospondin 1; TIMP2, tissue inhibitor of metalloproteinases-2; TMA, tissue microarray assembly; uPA, urokinase-type plasminogen activator.
1 These authors contributed equally to this work.
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In contrast with normal physiological stroma, which main-
tains epithelial cell polarity and inhibits epithelial cell growth and
transformation, tumour stroma may stimulate the whole tumour
development process [1]. In fact, presence of stromal desmo-
plastic reaction and stroma-rich tumours were both significantly
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associated with worse prognosis in breast cancer [2, 3]. In addi-
tion, a recent study classifying tumour stroma found that collagen
and fibroblast dominant groups were associated with poor out-
come [4].
Fibroblasts [also called CAFs (cancer-associated fibroblasts)],
the most abundant cell type in breast cancer stroma, produce a
plethora of chemokines, growth factors and ECM (extracellu-
lar matrix) proteins, all of which may contribute to increased
dissemination and metastasis [5].
Although no major morphologic differences are recognized
between CAFs and their normal counterparts, i.e. fibroblasts from
the matched adjacent uninvolved mammary tissue or reduction
mammoplasties, microarray and proteomic analysis revealed dis-
tinct mRNAs and protein expression profiles between them [6–
11].
In co-culture assays it was shown that CAFs may induce
epithelial cell proliferation and migration [12–15] and in an-
imal models it was reported that activated fibroblasts may act
as cofactors in cell transformation, promoting tumour develop-
ment from probably initiated, but still apparently normal mam-
mary cells [16]. In addition, a dynamic bidirectional signalling
between CAFs and breast cancer cells was detected, indicating
that the former may influence the transcriptional profile of breast
cancer cells and vice versa, the latter may affect the gene signature
of CAFs [14, 17].
It was reported that gene expression patterns from tumour
stromal cells may be correlated with disease-free survival in
breast cancer [7]. However, only a few works have directly ex-
amined stromal cells signature through microdissected samples
[7, 18], whereas others have used different models as fibroblasts
primary culture [10], tumour samples with differential contents
of stroma tissue [19] or a panel of previously identified ECM-
related genes [20], to estimate the influential effect of stroma in
breast cancer behaviour.
Axillary nodes status is one of the established prognostic
factors in breast cancer. However, to the present date, there is
no consensus of which specific proteins, synthesized by CAFs,
might be related with lymph node involvement. To address this
issue a systematic review of studies evaluating CAF biomarkers
associated with the presence of regional metastasis was under-
taken and selected markers were further analysed in samples from




PubMed was searched by two reviewers (SM and MLHK or
RAR) for relevant trials using the following words: ‘breast can-
cer’ and ‘lymph node’ and fibroblast or stroma or microenviron-
ment. Electronic search was performed on March 4, 2013.
Inclusion criteria
Studies presenting data on specific biomarker in CAFs or stromal
cells in the primary tumour and involvement of lymph nodes were
included. Studies evaluating the stroma compartment without a
specific reference to each cellular element were excluded, as well
as studies employing mRNA analysis by RT–PCR or microar-
ray without microdissection. At first, we did not exclude studies
evaluating nodal status and stromal cells gene expression pro-
files, however, as tumour samples were not microdissected and
results were based on indirect analysis, these works were then
excluded. Studies evaluating fibroblasts for loss of heterozygosis
and point mutations, studies in cell culture or animal models or
other diseases than breast cancer and studies without reference
to the nodal status of patients were also excluded. Only studies
in English language with an available abstract through Pubmed
were included (figure 1).
Seven reviews were identified, three of which, written before
1997, were not available as a full-text paper [21–23]. The other
four reviewed pathways in breast cancer development: RANK–
RANKL system, CCN6 and TGFβ (transforming growth factor
β) or mainly dealt with immune system cells and were not further
analysed [24–27]. All the cited references were checked. No
systematic reviews were identified.
Patients
Breast cancer samples from 65 patients undergoing breast sur-
gery at Hospital Samuel Libaˆnio, in Pouso Alegre, MG, Brasil
from 1997 to 2005, were retrospectively analysed. This study
was approved by the Institutional Ethics Committee of Hos-
pital Samuel Libaˆnio (no. 1119/09). Mean age of patients was
57.78 +− 13.9 years (range: 23–84 years). All patients were dia-
gnosed with IDCs (invasive ductal carcinomas), 54 % of whom,
presenting involved axillary nodes, and 24.6, 40.0 and 32.9 %
with disease clinical stages I, II or III, respectively (two un-
known). ER (oestrogen receptor), PR (progesterone receptor) and
HG3 (histological grade 3) were detected in 58.7, 50 and 40 % of
the samples, respectively.
TMA (tissue microarray assembly)
Paraffin blocks of the primary tumours were reviewed for the
selection of a representative area of tumour stroma, which was
then collected using a Manual Tissue Arrayer-1 (Beecher Instru-
ments). Samples were orderly arranged in a grid and the first core
was represented by a fragment of normal liver used as a refer-
ence. Samples of 3 μm were then placed on slides using special
adhesives (Instrumedics Inc.). To obtain two levels of the same
samples on the TMA, two sets of tumour triplets were assembled
on the slides with a gap of 40 cuts between them. A second TMA
was assembled containing mainly cancer cells.
Immunohistochemistry
Immunohistochemistry reactions were analysed using optical mi-
croscope Nikon Eclipse E200 ((Nikon Instruments), magnifica-
tion: 400×, aperture of the objective lenses: 40×/0.65 (∞/0.17-
WD0.65) and temperature: 20 ◦C/68 ◦ F equipped with Motic
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Figure 1 Stages of the search strategy
1000 camera). The images were acquired by Motic Images Plus
2.0. Tissue sections were deparaffinized in xylene and rehydrated
with graded ethanol. Antigen retrieval was performed using a
pressure cooker in citrate buffer pH 6.0, followed by endogenous
peroxidase blocking with hydrogen peroxidase solution (3 %).
Sections were then incubated with primary monoclonal antibod-
ies: MMP13 (matrix metalloproteinase 13) (1:150, diluted Clone
VIIIA2 from Lab Vision Corporation), CAV1 (caveolin-1; 1:800,
from Cell Signaling Technology) and PDPN (podoplanin; clone
D2–40, from Signet Laboratories). After primary antibody in-
cubation and pos primary blocking a polymer-peroxidase (No-
volink, Novocastra, Leika Biosystems) amplification step was
done. Antigen detection was carried out in a solution containing
3,3-diaminobenzidine (Sigma) and 6 % (v/v) H2O2. Counterstain-
ing was performed with Harris haematoxylin (Merck).
A three-grade system was used to evaluate PDPN and CAV1
expression in stromal cells. CAV1 staining in stromal cells was
graded as follows: negative expression ( − ),  5 %; low expres-
sion ( + ), 5–50 %; and high expression ( + + ), >50 %. PDPN
was evaluated as: negative expression ( − ),  10 %; low expres-
sion ( + ), 10–50 %; and high expression ( + + ), >50 % [28,29].
Both the intensity and percentage of positivity were assessed to
define the expression of MMP13. No brown particle staining: 0;
light brown particle in cytoplasm: 1; moderate brown particle: 2;
and dark brown particle: 3. The percentage of positive cells was
classified into four groups. 1: <25 %; 2: 25–50 %; 3, 51–75 %
and 4,>75 % positive cells. The SI (staining index), the sum of
the intensity and the percentage of positive staining, was used
to define high (SI  6) or low (SI  6) expression of MMP13
[30].
Statistical analysis
Pearson χ 2 and OR (odds ratio) were calculated using SPSS
11.0 version software (SPSS), and P value<0.05 was considered
significant.
RESULTS
The aim of this study was to address the following question:
Does the expression of stromal cell biomarkers increase the risk
of presenting lymph node metastasis in breast cancer?
To accomplish this aim a comprehensive literature search for
all studies addressing the relationship between biomarker expres-
sion in stromal cells and lymph node involvement was conducted
(Figure 1).
At first, 297 titles were retrieved from which, six fulfilling the
inclusion criteria. Two manuscripts [31,32] were subsequently
added by MMB after reviewing her archives, one of them, a ref-
erence in one of the 78 full texts analysed [33]. Hence, eight
manuscripts were reviewed. Most exclusions were taken for ab-
sence of lymph node data, exclusive analysis in node positive
or negative disease; analysis of the stroma compartment but not
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specifically of the stromal cells. In total, 1408 patients were ana-
lysed and their clinical characteristics appear in Table 1.
Biomarkers evaluated in the reviewed studies may be di-
vided into two groups, according to their ontology: extracel-
lular matrix components [MMP13, TIMP2 (metallopeptidase
inhibitor 2), THBS1 (thrombospondin 1), LGALS1 (lectin,
galactoside-binding, soluble, 1)] and response to wounding
[PDPN, PLAU (plasminogen activator, urokinase), PLAUR
(plasminogen activator, urokinase receptor), CAV1, LGALS1 and
THBS1].
In the first group, positive expression of MMP13 and
LGALS1 in CAFs was associated with enhanced OR for regional
metastasis [30, 34]. Contrariwise, positive expression of THBS1
showed a trend towards decreased OR for nodal involvement and
TIMP2 expression was not associated with lymph node meta-
stasis [35,36]. A combined evaluation of the expression of these
extracellular matrix components (MMP13, TIMP2, LGALS1 and
THBS1) in CAFs was now performed and found to be associated
with an increased OR for involved nodes (table 2).
In the group of biomarkers involved in response to wounding
(PDPN, PLAU, PLAUR, CAV1, THBS1 and LGALS1), two
studies evaluated PDPN expression in CAFs, with contrasting
results: one of them showed an increased and the other one
a decreased OR for lymph node involvement [28, 32]. In
addition, one study evaluated the expression of three proteins,
PLAU, PLAUR and PAI1 (plasminogen activator inhibitor-1), in
CAFs from the same tumour samples, but found no association
with lymph node metastasis [31]. In another work, CAV1
positive staining of fibroblasts was associated with decreased
OR for axillary involvement [37]. A combined evaluation
of expression of response to wounding biomarkers was not
associated with differential OR for involved nodes, as shown in
Table 2.
After the systematic review, three biomarkers found associated
with nodal metastasis, MMP13, PDPN and CAV1, were selected
for further evaluation in a group of 65 patients with involved or
uninvolved nodes (56 and 44 % of them, respectively). Expression
analysis was determined in stroma-rich areas by immunohisto-
chemistry reactions in TMA, as shown in Figure 2.
Metalloproteinase 13 expression was detected as a cytoplas-
mic staining in both CAFs, as well as malignant cells, in all
tumour samples, except one. In CAFs, MMP13 strong expres-
sion evaluated as staining index  6 was observed in 63.9 %
of the samples (39/61). PDPN expression was also detected as
a cytoplasmic staining in 73 % of CAFs (46/63). It was also
observed in malignant cells in two tumour samples. Caveolin
expression was detected on the membrane and/or cytoplasm of
CAFs, exclusively (but not in malignant cells). In addition, cave-
olin expression was detected in at least 50 % of CAFs in 42.6 %
of the samples (26/61).
In the present work no association between expression of these
three proteins (MMP13, PDPN and CAV1) and lymph node in-
volvement was found (table 2).
A metanalysis including present and previous results in-
dicate that PDPN expression in CAFs is not associated with
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Table 2 Immunoexpression of biomarkers in breast cancer stromal cells and OR for positive nodes (N+ )
(1) staining index (SI: product of intensity and percentage of positive staining, high:SI  6, at least 25% cells with moderate staining); (2) Positive
cells >11%; (3) Combined scores of the sum of staining intensity and percentage positive cells: (− )= no staining, (+ )=weak, (+ + )=moderate,
(+ + + )= strong (4) strong: at least 30% positive cells; (5) expression 10% of the tumour stroma; (6) positive: ratio of podoplanin-positive
stromal area to overall stromal area 10%; (7) negative (no staining), weak (definite but weak staining), strong (intense staining); (8) absent
(no staining), present (either diffuse weak to strong staining); (9) expression 50% of the tumour stroma. Combined OR for N+ consider-
ing studies reporting analysis of more than one biomarker: ECM (MMP13/TIMP2/LGALS1/THBS1); PDPN (b+ c) and Response to wounding
(LGALS1/THBS1/PDPN(b+ c)/CAV1/PLAU or PLAUR).
(a)
Study Biomarker N+ (%) N− (%) OR (95%) P
Zhang et al. [30] MMP13(a) High(1) 66 43 2.57 (1.56–4.23) < 0.001
Nakopoulou et al. [36] TIMP2 >11%(2) 73 82 0.58 (0.24–1.34) 0.201
Ioachim et al. [35] THBS1 (+ /+ + /
+ + + )(3)
41 62 0.44 (0.19-1.03) 0.06
Jung et al. [34] LGALS1 Strong(4) 70 51 2.31 (1.02–5.23) 0.04
ECM (MMP13/TIMP2/LGALS1/THBS1) Positive 63 55 1.41 (1.02–1.96) 0.04
Schoppmann et al. [32] PDPN(b) 10%(5) 4 12 0.32 (0.14–0.77) 0.008
Pula et al. [28] PDPN(c) 10%(6) 91 73 3.87 (1.31-1.42) 0.010
PDPN (b + c) 10% 27 26 1.09 (0.72–1.63) 0.67
Dublin et al. [31] PLAU Strong(7) 46 41 1.23 (0.58–2.61) 0.58
Dublin et al. [31] PLAUR Strong(7) 54 66 0.61 (0.28–1.31) 0.20
Dublin et al. [31] PAI1 Strong(7) 17 11 1.61 (0.53–4.86) 0.39
Witkiewicz et al. [37] CAV1(d) Present(8) 46 76 0.27 (0.12–0.63) 0.002
Response to wounding
(LGALS1/THBS1/PDPN(b,c)/CAV1/PLAU)
Positive 39 40 0.97 (0.75–1.27) 0.83
Response to wounding
(LGALS1/THBS1/PDPN/(b,c)/CAV1/PLAUR)
Positive 40 42 0.93 (0.71–1.21) 0.60
(b)
Study Biomarker N+ N− OR (95%) P
Present results MMP13(e) High(1) 63 64 0.97 (0.34–2.78) 0.958
PDPN(f) 10%(6) 79 65 2.03 (0.65 – 6.29) 0.361
CAV1(g) >50%(9) 41 45 0.84 (0.30–2.33) 0.74
Metanalysis (previous studies + present
results)
MMP13 (a+ e) n=324 High 66 47 2.15 (1.38-3.37) 0.001
PDPN (b+ c+ f) n=546 10% 34 30 1.25 (0.87–1.79) 0.128
CAV1 (d+ g) n=165 >50% 44 64 0.43 (0.23–0.81) 0.007
associated with increased and decreased OR, respectively, for
axillary involvement (table 2).
DISCUSSION
Some studies have pointed out that a reactive stroma may negat-
ively affect disease outcome in breast cancer [7, 20]. However,
tumour microenvironment reflects stromal cells behavior and ex-
tracellular matrix content, which is determined by both stromal
and cancer cells. Our aim was to evaluate which biomarkers ex-
pressed by stromal cells might be associated with the risk of
positive nodes in breast cancer.
Two studies have previously directly analysed microdissected
stromal cells from breast cancer samples describing stromal sig-
natures predictive of poor outcome, but none of them specifically
reported nodal involvement [7, 18]. One of these works described
a reactive stroma profile, characterized by an increased expres-
sion of genes encoding ECM components, proteolytic enzymes
and adhesion receptors [18]. In addition, some other stromal sig-
natures indirectly identified, i.e., not from microdissected stromal
cells, were also shown to have prognostic value [19, 20, 38].
As tumour metastasis involves a series of steps, including
a reactive stroma, partly secreted by stromal cells, a relative
high number of manuscripts were expected in this systematic
review. However, after exclusions, eight studies were retrieved, all
performed in tissue samples examined by immunohistochemistry.
In these works, protein expression was specifically described in
CAFs or stromal cells.
The studies identified in the present review, mainly focused
on classical markers synthesized by stromal cells, as extracellu-
lar matrix components (MMP13, TIMP2, THBS1 and LGALS1)
and proteins involved in response to wounding (PDPN, PLAUR,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2013 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
925
M. A. A. K. Folgueira and others
Figure 2 Immunohistochemical staining of MMP13 (A and B),
PDPN (C and D) and CAV1 (E and F) in CAFs from breast can-
cer samples from patients with involved (N+ ) and uninvolved
(N0) nodes
Positive immunostaining indicated (arrows). Original
magnification: MMP13: ×100, CAV1: ×400, PDPN: ×100.
PLAU, CAV1, LGALS1 and THBS1). However, except for PDPN
determinations, we could identify only one work analysing ex-
pression of each of these markers.
Extracellular matrix signatures were previously shown to be
related with tumour outcome and a variety of metagenes were
described, including metalloproteases, whose expression levels
were associated with breast cancer survival [18, 20, 38]. In the
works reviewed in this analysis [30, 34-36], a positive expression
of MMP13 and LGALS1 by stromal cells was associated with
increased OR for nodal involvement, in contrast with positive
THBS1 expression that showed a trend towards association with
decreased OR for node positivity. A combined analysis of ECM
components was performed, however, statistical significance to
detect nodal involvement was not improved, probably because it
involves expression of proteins with different functions and odds
ratios in opposite directions.
Matrix metalloproteases are proteins involved in the break-
down of extracellular matrix. Among them, a higher immunoex-
pression of MMP13 (collagenase 3) in stromal cells was asso-
ciated with positive nodes in breast cancer [30]. In agreement,
MMP13 expression by intratumoural fibroblasts was signific-
antly associated with shorter relapse-free survival in luminal A
tumours [39]. However, MMP13 was also detected in the cyto-
plasm of cancer cells [40] and its high immunoexpression was
also associated with poor outcome [30]. In addition, whole tu-
mour MMP13 protein amount, analysed from tumour lysates and
reflecting tumour and stromal cells, as well as ECM content, was
not correlated with nodal status [41]. In accordance, MMP13 high
expression in CAFs was not associated with axillary involvement
in the present work. Hence, there is no consensus and it seems
likely that a fine tune in MMP13 tumour content is involved in
regulating nodal metastasis.
TIMPs are endogenous regulators of MMPs with contradictory
activities as inhibiting MMPs and promoting tumour cell growth.
In breast cancer, TIMP2 immunoexpression may be localized in
cancer as well as stromal cells, however mRNA in situ hybridiz-
ation indicates a lower TIMP2 synthesis in stromal cells than in
tumour cells [42]. It was shown that TIMP2 protein expression
in stroma cells may be inversely correlated with tumour size;
however, there was no association with lymph node involvement
[36].
Galectin 1 is a beta galactoside-binding protein which may
be involved in tumour progression. Galectin 1 is synthesized by
cancer as well as stromal cells and its overexpression in both cell
types in breast cancer samples, indistinctly, was also associated
with high tumour grade, a poor prognosis marker [43]. In agree-
ment, Galectin 1 stromal cell expression was another predictive
marker of node involvement [34].
Thrombospondin (THBS1) is an antiangiogenic extracellular
matrix protein that inhibits tumour growth and metastasis in an-
imals. Although there is no consensus of its clinical relevance,
there is a trend towards an inverse correlation between increased
THBS1 expression in tumour stroma (evaluated as stromal area)
or stromal cells and nodal positivity [35, 44]. These studies were
not analysed together in the present systematic review as one of
them [44] evaluated THBS1 in the stromal area but not specific-
ally in the stroma fibroblasts.
PDPN is a type-I integral membrane glycoprotein, which ex-
pression was shown up-regulated in a number of different cancers
[45]. Two studies evaluating stromal cells PDPN immunoex-
pression, using equivalent cut-offs, reported contrasting results.
PDPN loss of positivity in stromal cells was associated with
presence of lymph node metastasis in one [32] but not in another
study [28]. In the present work, PDPN expression in CAFs was
not related with axillary involvement, further indicating that its
relationship remains elusive.
The uPA (urokinase-type plasminogen activator/PLAU) and
its main inhibitor PAI1 play key roles in tumour-associated pro-
cesses and their elevated expression is correlated with negative
outcomes in node negative breast cancer. However, clinical utility
of these molecules as prognostic markers is limited by the use of
ELISA tests for their detection in fresh or frozen tissue [46]. It
is unclear whether their relative levels in the tumour stroma or
in the tumour cells themselves are the most relevant to patient
outcome. Using microdissected stromal and cancer cells it was
shown that similar expression levels occur in both compartments
and that quantity of tumour stroma in the tumour tissue specimen
is not relevant [47]. However, in node negative patients, immun-
ohistochemistry study has shown that both fibroblastic PAI1 and
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diffuse stromal uPA are associated with local recurrence [48] and
even though fibroblastic expression of uPA and uPAR (urokinase-
type plasminogen activator receptor) and strong PAI1 expression
was related to the presence of invasion or tumour size, it was not
associated with node metastasis [31].
CAV1 is an important component of caveolae membranes and
loss of CAV1 in the fibroblast compartment, rather than within
breast cancer tumour cells was shown to be an independent
predictor of lymph node metastasis and poor outcome [37]. In
addition, it was reported that high levels of CAV1 in the stromal
breast cancer tissue were associated with reduced frequency of
nodal metastasis and improved survival [49]. These results, how-
ever, were not confirmed in the present series of IDC nor by other
authors [29] who could neither verify an association between loss
of stromal CAV1 and the occurrence of positive lymph nodes.
Discrepancies may in part be due to tumour heterogeneity. Breast
cancer is believed to be a heterogeneous disease and expression
of stromal biomarkers may be connected to particular subtypes of
breast carcinoma, as recently suggested [50]. Variations in ex-
pression of biomarkers in fibroblasts between different histo-
logical types was reported, demonstrating that invasive ductal
breast carcinomas have high global expressions of MMPs, includ-
ing MMP13, and TIMPs compared with the remaining types of
breast carcinoma [51]. Furthermore, CAFs are identified by a
lot of markers such as αSMA, S100A4, possibly because they
originated from heterogeneous population [52], raising the pos-
sibility that specific subtypes of CAFs may be associated with
different frequencies of the chosen markers.
In conclusion, only few works specifically evaluated bio-
marker expression in CAFs and their relation with nodal involve-
ment. These studies were concerned in evaluating expression
of extracellular matrix components and proteins involved in re-
sponse to wounding, which are believed to be mainly synthesized
and secreted by fibroblasts. In summary, there is some evidence
that a high expression of MMP13 and PDPN may be related with
increased OR for positive nodes and a positive expression of
CAV1 with decreased OR for positive nodes. Breast cancer sub-
types based on tumour transcriptional profile were shown to have
prognostic importance. Hence, it would be interesting to ana-
lyse CAFs role in tumour aggressiveness in each specific breast
carcinoma subtype, as well the relationship between stromal bio-
markers and different CAF subsets.
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